Core Thesis - Veeva Systems Inc. (VEEV) is viewed as a compelling investment opportunity due to its durable, high-margin vertical SaaS business model, particularly in the life sciences sector, and its attractive valuation despite recent market drawdowns [2][4][5] Financial Performance - Veeva has demonstrated strong financial metrics, including a five-year revenue CAGR of approximately 17%, free cash flow (FCF) margins around 40%, and a net cash balance of $6.4 billion, which provides strategic flexibility [4][5] - The company's stock was trading at $185.28 as of March 16th, with trailing and forward P/E ratios of 34.06 and 20.92 respectively [1] Business Model and Market Position - Veeva specializes in cloud applications for life sciences, embedding itself in workflows that are expensive and highly regulated, with its CRM business contributing only about 20% of total revenue [2][3] - The broader Veeva suite includes around 50 applications that benefit from structural moats and high switching costs, making the platform essential for clients [3][4] AI Integration and Future Growth - Veeva is positioned as a leader in vertical market AI, with initiatives that automate labor-intensive workflows, enhancing productivity and delivering cost savings [4][5] - The transition of CRM to the Vault platform is expected to enhance cross-selling opportunities and accelerate AI adoption, contributing to future growth [3][5] Market Outlook - The company is projected to have an 83% upside to approximately $400 by the end of 2027, implying a 27% internal rate of return (IRR) for investors [5] - As competitive fears in the CRM space diminish and AI adoption accelerates, VEEV is anticipated to experience a re-rating in the market [5][6]

Core Insights - Brown Capital Management's Small Company Fund underperformed in Q4 2025, with a decline of 1.50% compared to the Russell 2000® Growth index's gain of 1.22% [1] - The Fund's performance for the entire year of 2025 was down 11.46%, significantly lagging behind the Index's return of 13.01% [1] - The Fund's investment strategy is based on company fundamentals, which showed strong revenue and earnings growth in 2025 [1] Company Focus: Veeva Systems Inc. - Veeva Systems Inc. (NYSE:VEEV) is a technology company providing a cloud-based software platform for the life sciences industry, with a market capitalization of $29.64 billion [2] - The stock of Veeva Systems Inc. experienced a one-month return of -19.57% and a 52-week decline of 20.26% [2] - Veeva Systems was identified as a detractor from the Fund's performance in Q4 2025, despite its strong market position and innovative solutions in the life sciences sector [3] - The company's offerings include Veeva Customer Relationship Management (CRM) and Veeva Vault, which have established a dominant market position and present opportunities for growth in clinical applications [3] - Veeva's client base includes major global pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, Eli Lilly, Merck, and Novartis [3]

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score identifies undervalued stocks using ratios like P/E, PEG, and Price/Sales to find attractive investment opportunities [3] - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow for sustainable growth [4] - The Momentum Score helps investors capitalize on price trends, using factors like one-week price changes and monthly earnings estimate changes [5] - The VGM Score combines the three Style Scores to identify stocks with the best value, growth forecasts, and momentum, serving as a strong indicator alongside the Zacks Rank [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize returns, while stocks with a 3 (Hold) rank should also have favorable Style Scores for potential upside [9] Company Spotlight: Veeva Systems - Veeva Systems Inc. specializes in cloud-based software applications and data solutions for the life sciences sector, offering products like Veeva CRM and Veeva Vault [11] - VEEV holds a 3 (Hold) Zacks Rank with a VGM Score of A and a Growth Style Score of B, indicating a projected year-over-year earnings growth of 19.9% for the current fiscal year [12] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate increasing by $0.13 to $7.91 per share, and an average earnings surprise of +8.2% [12][13]

Core Insights - The year 2025 is expected to be a turning point in global healthcare, driven by digital transformation and operational pressures, with significant backing from initiatives like Trump's $500 billion Stargate AI project [1][6] - The Medical Info Systems industry is projected to grow rapidly, with the health tech market anticipated to expand from $880 billion in 2025 to $3.3 trillion by 2034, driven by demand for telehealth, AI, IoMT, and cybersecurity [1][2] Industry Overview - The Zacks Medical Info Systems industry includes companies that develop healthcare information systems, providing software and hardware solutions for secure access to real-time data [3] - The focus on patient satisfaction and data security has increased the demand for big data, cloud computing, blockchain, and AI solutions [3] Trends Impacting the Industry - AI adoption in healthcare is significant, with applications in drug synthesis, diagnostics, and patient monitoring, supported by initiatives like the Stargate project [4] - The global AI in healthcare market is projected to reach $95.65 billion by 2025, indicating strong growth potential [4] - The demand for remote healthcare is increasing, with the smart healthcare products market valued at $145.9 billion in 2023 and expected to grow to $485.71 billion by 2032, at a CAGR of 12.78% [5] Challenges Facing the Industry - The $500 billion Stargate AI initiative faces challenges from new tariffs, which have increased costs for critical AI infrastructure by 10-25%, leading to delays in hardware upgrades [6] - Tariffs on copper, aluminum, and steel are expected to raise production costs, with 88% of healthcare executives anticipating price hikes of at least 18% [6] Industry Performance - The Zacks Medical Info Systems industry ranks 88, placing it in the top 36% of over 250 Zacks industries, indicating strong near-term prospects [8] - The industry has outperformed the S&P 500 and the Zacks Medical sector over the past year, gaining 12% compared to the sector's decline of 15.4% [10] Current Valuation - The industry is currently trading at a forward price-to-sales (P/S) ratio of 5.54X, compared to the S&P 500's 5.25X and the sector's 2.23X [13] Investment Opportunities - Companies like Veeva Systems, 10x Genomics, and Insight Molecular Diagnostics are highlighted as potential investment opportunities, with strong earnings outlooks [2][18][21][25] - Veeva Systems is expected to report a 15.8% improvement in fiscal 2026 earnings, with revenue growth of 12.8% [19] - 10x Genomics anticipates a 27.8% jump in earnings for 2026, with revenue growth of 5.8% [22] - Insight Molecular Diagnostics projects a 43.5% increase in earnings for 2025 [26]

Core Insights - The Medical Info Systems industry is experiencing significant growth driven by new federal policies and the $500 billion Stargate AI project initiated by Donald Trump, which aims to enhance AI infrastructure in healthcare [1][3][5] - The use of AI in the medical device market is projected to grow at a CAGR of 29.9% from 2026 to 2029, indicating strong demand for digital healthcare solutions [1][3] - The industry faces challenges due to escalating tariffs on imports, which could hinder the development of AI technologies essential for healthcare [2][5] Industry Overview - The Zacks Medical Info Systems industry includes companies that develop healthcare information systems, providing software and hardware solutions for secure access to clinical, administrative, and financial data [2] - The focus on patient satisfaction and data security has increased the demand for big data, cloud computing, blockchain, and AI technologies [2] Trends Influencing the Industry - AI is being increasingly adopted in the medical sector for drug synthesis, device creation, and diagnostics, with the global AI in healthcare market expected to reach $95.65 billion by 2025 [3] - Remote patient monitoring is growing rapidly due to the rise in wearable devices and telehealth services, with the global smart healthcare products market projected to grow from $145.9 billion in 2023 to $485.71 billion by 2032, at a CAGR of 12.78% [4] Financial Performance - The Zacks Medical Info Systems industry has underperformed the S&P 500 and the broader medical sector over the past year, with a decline of 6.6% compared to a 25.3% increase in the S&P 500 [9] - The industry is currently trading at a forward price-to-sales (P/S) ratio of 3.95, lower than the S&P 500's 4.56 and the sector's 2.50 [12] Investment Opportunities - Veeva Systems, with a Zacks Rank 1 (Strong Buy), is expected to see an 11% earnings growth for fiscal 2026 [18] - Hims & Hers Health, holding a Zacks Rank 2 (Buy), anticipates a 58% increase in earnings for 2025, driven by a growing subscriber base [22] - Butterfly Network, also with a Zacks Rank 2, projects a 5.9% improvement in earnings for 2025 [26]